


## Mutated EGFR-IN-2

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-128860   |
| CAS No.:           | 2050906-97-1  |
| Molecular Formula: | C <sub>29</sub> H <sub>35</sub> N <sub>8</sub> O <sub>3</sub>                             |
| Molecular Weight:  | 562.64  |
| Target:            | EGFR  |
| Pathway:           | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK   |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |  |                       |                         |   |
|-------------------------------------|--|-----------------------|-------------------------|---|
| <b>Description</b>                  | Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC <sub>50</sub> =1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor activity <sup>[1]</sup> . |                       |                         |   |
| <b>IC<sub>50</sub> &amp; Target</b> | EGFR <sup>T790M</sup>  | EGFR <sup>L858R</sup> | EGFR <sup>ex19del</sup> | EGFR (L858R/T790M)<br><1 nM (IC <sub>50</sub> ) |
|                                     | EGFR (ex19del/T790M)   |                       |                         |   |

### REFERENCES

[1]. 2, 4-di-(nitrogen containing group) substituted pyrimidine compound and preparation method and use thereof.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA